Skip to main content

Table 2 Risk factors of systemic fungal infection

From: Oral nystatin prophylaxis to prevent systemic fungal infection in very low birth weight preterm infants: a randomized controlled trial

Variables Nystatin group Control group p-value
(n = 47) (n = 48)  
Duration of stay in NICU, n (%)
 Mean duration time, days, mean (± SD) 9.8 (±14.9) 13.6 (±15.5) 0.23
  ≤ 7 days, n (%) 8 (17.0) 8 (16.7) 0.16
  > 7 days, n (%) 18 (38.3) 27 (56.3)  
Use of peripheral venous access, n (%) 47 (100) 48 (100) 1.00
 Duration of peripheral venous access (days) 24 (6–42) 28 (5–62) 0.18
Use of central venous access, n (%) 38 (80.9) 37 (77.1) 0.80
 Duration of central venous access (days) 19 (0–42) 19 (0–42) 0.96
Use of orogastric tube, n (%) 47 (100) 47 (97.9) 1.00
 Duration of orogastric tube (days) 30 (8–42) 30 (8–42) 0.76
Use of endotracheal tube, n (%) 10 (21.3) 16 (33.3) 0.19
 Duration of endotracheal tube (days) 2.6 (0–21) 4.29 (0–31) 0.26
Use of antibiotic therapy, n (%) 43 (91.5) 46 (95.8) 0.44
 Duration of antibiotic therapy (days) 19 (0–42) 21 (0–42) 0.4
Use of aminophylline, n (%) 28 (59.6) 35 (72.9) 0.17
 Duration (days) 11 (1–42) 13 (3–42) 0.42
Use of steroid, n (%) 3 (6.4) 3 (6.3) 0.65
 Duration (days) 1 (0–12) 1 (0–3) 0.38
Use of parenteral nutrition, n (%) 45 (95.7) 47 (97.9) 0.62
 Duration (days) 21 (0–41) 22 (0–42) 0.53
 Duration of parenteral lipid (days) 16 (0–40) 19 (4–39) 0.15
  1. Data are presented in median (range) or proportion